F. Hoffmann-La Roche Ltd

<!-- Name:DistributionId Value:1000797310 --> <!-- Name:NewsArchiveTags Value:9015,9014 --> <!-- Name:NewsArchiveOrgTags…

<!-- Name:DistributionId Value:1000784225 --> <!-- Name:NewsArchiveTags Value:9014 --> <!-- Name:NewsArchiveOrgTags…

<!-- Name:DistributionId Value:1000781820 --> <!-- Name:NewsArchiveTags Value:9015,9014 --> <!-- Name:NewsArchiveOrgTags…

<!-- Name:DistributionId Value:1000781880 --> <!-- Name:NewsArchiveTags Value:9014 --> <!-- Name:NewsArchiveOrgTags…

<!-- Name:DistributionId Value:1000780297 --> <!-- Name:NewsArchiveTags Value:9014 --> <!-- Name:NewsArchiveOrgTags…

<!-- Name:DistributionId Value:1000780320 --> <!-- Name:NewsArchiveTags Value:9014 --> <!-- Name:NewsArchiveOrgTags…

<!-- Name:DistributionId Value:1000780065 --> <!-- Name:NewsArchiveTags Value:9015,9014 --> <!-- Name:NewsArchiveOrgTags…

This new test for researchers specifically targets the XBB.1.5 Omicron sub-variant and runs on the real-time PCR platforms LightCycler® 480 II* and cobas® z480.Results from the test will help closely track the virus’ lineage and provide…

Pivotal Phase III IMbrave050 study investigating Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant…

Xofluza is now approved in the EU for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza in children aged one year and above, and in adolescents and adultsXofluza is the first influenza antiviral with a…